

I. OVERVIEW OF THE FUNDING OPPORTUNITY

Program Announcement for the Department of Defense

Defense Health Program

Congressionally Directed Medical Research Programs

Military Burn Research Program

Clinical Translational Research Award

Announcement Type: Modified

Funding Opportunity Number: HT9425-23-MBRP-CTRA

**Assistance Listing Number: 12.420 Military Medical
Research and Development**

SUBMISSION AND REVIEW DATES AND TIMES

- **Pre-Application Submission Deadline:** 5:00 p.m. Eastern time (ET), May 31, 2023
- **Invitation to Submit an Application:** July 18, 2023
- **Application Submission Deadline:** 11:59 p.m. ET, September 5, 2023
- **End of Application Verification Period:** 5:00 p.m. ET, September 12, 2023
- **Peer Review:** November 2023
- **Programmatic Review:** January 2024

This program announcement must be read in conjunction with the General Application Instructions, version 803. The General Application Instructions document is available for downloading from the Grants.gov funding opportunity announcement by selecting the “Package” tab, clicking “Preview,” and then selecting “Download Instructions.”

TABLE OF CONTENTS

I. OVERVIEW OF THE FUNDING OPPORTUNITY.....	1
II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY.....	3
II.A. Program Description.....	3
II.A.1. FY23 MBRP Focus Areas	4
II.A.2. Award History	4
II.B. Award Information	5
II.C. Eligibility Information.....	9
II.C.1. Eligible Applicants	9
II.C.2. Cost Sharing.....	10
II.C.3. Other	10
II.D. Application and Submission Information.....	10
II.D.1. eBRAP and Grants.gov	10
II.D.2. Content and Form of the Application Submission	11
II.D.3. Unique Entity Identifier (UEI) and System for Award Management (SAM)	34
II.D.4. Submission Dates and Times.....	34
II.D.5. Funding Restrictions.....	35
II.D.6. Other Submission Requirements	36
II.E. Application Review Information	36
II.E.1. Criteria	36
II.E.2. Application Review and Selection Process.....	40
II.E.3. Integrity and Performance Information.....	41
II.E.4. Anticipated Announcement and Federal Award Dates.....	41
II.F. Federal Award Administration Information	41
II.F.1. Federal Award Notices.....	41
II.F.2. Administrative and National Policy Requirements	42
II.F.3. Reporting.....	43
II.G. Federal Awarding Agency Contacts.....	44
II.G.1. eBRAP Help Desk.....	44
II.G.2. Grants.gov Contact Center	44
II.H. Other Information.....	44
II.H.1. Program Announcement and General Application Instructions Versions.....	44
II.H.2. Administrative Actions.....	45
II.H.3. Application Submission Checklist	47
APPENDIX 1: ACRONYM LIST	49
APPENDIX 2: DOD AND VA WEBSITES.....	51

II. DETAILED INFORMATION ABOUT THE FUNDING OPPORTUNITY

II.A. Program Description

Applications to the Fiscal Year 2023 (FY23) Military Burn Research Program (MBRP) are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA) using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The execution management agent for this program announcement is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC). The MBRP was initiated in 2011 to address combat-related and trauma-induced burn injuries as well as to improve health and performance outcomes for Service Members and the general public. Appropriations for the MBRP from FY11 through FY22 totaled \$100 million (M). The FY23 appropriation is \$10M.

The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public.

Burn injuries sustained by military Service Members while in the line of duty, whether on the battlefield, or in a military training environment, represent a continuous health burden on both the injured Service Member and the Department of Defense (DOD) health care systems in which they receive care. Historically, burn injuries afflicted some 5% to 20% of casualties during post-World War II conflicts.¹ In recent years, burns sustained during Operation Iraqi Freedom/Operation Enduring Freedom affected nearly 9% of combat-related casualties.² While thermal burns represent the most common mechanism of burn injury, other injurious mechanisms such as frostbite, high-voltage electrical, chemical, directed energy, and radiation/nuclear exposure represent an additional formidable threat to the health and well-being of Service Members. The Armed Forces Health Surveillance Division reports an increased number of cold-related injuries in recent years; high-voltage accidents occur on and off the battlefield; and the threat of chemical, nuclear, or directed energy weapons is an ever-present danger. Regardless of mechanism, combat-associated burn injuries are devastating due, in part, to the high incidence of concurrent severe traumatic injuries. In addition, burns sustained in a deployed environment more often lead to severe burns than those sustained in the civilian setting. The majority of combat burns sustained in recent conflicts resulted from explosive device detonation, leading to a greater Injury Severity Score, an increase in inhalation injuries, and a larger, full-thickness burn size.³ It is anticipated that in future conflicts the explosive weaponry used against U.S. forces will be more powerful than that seen in the past, likely resulting in a higher number of casualties with significant injuries and larger, more severe burns. Furthermore, the care provided to

¹ Kauvar DS, Wade CE, and Baer DG. 2009. Burn hazards of the deployed environment in wartime: Epidemiology of noncombat burns from ongoing United States military operations. *Journal of the American College of Surgeons* 209(4):453-460.

² Escolás SM, Archuleta DJ, Orman JA, et al. 2015. Postdischarge cause-of-death analysis of combat-related burn patients. *Journal of Burn Care and Research: Official Publication of the American Burn Care Association* 38(1):e158-e164.

³ Kauver DS, Cancio LC, Wolf SE, et al. 2006. Comparison of combat and non-combat burns from ongoing U.S. military operations. *The Journal of Surgical Research* 132:195-200.

Service Members in a combat environment where evacuation may be significantly delayed may impact clinical outcomes. Irrespective of the injury mechanism, prolonged delay to definitive care renders assessment and treatment of burn wounds at or close to the point of injury challenging to medical and non-medical first responders alike. The time is long past for the burn care community to develop, refine, or test novel therapies or technologies that would allow for better provision of care and improved patient outcomes, particularly in resource limited settings.

II.A.1. FY23 MBRP Focus Areas

In order to meet the MBRP mission to “identify and close gaps in combat burn trauma care through military-focused research,” the program seeks to fund research that enhances the ability to prevent, assess, and/or treat burns/burn-associated complications, which ultimately facilitates the improvement of health and performance outcomes of burn-injured Service Members, Veterans, military beneficiaries, and/or the American public. In addition, the Program is especially interested in research projects focusing on products that can be used by pre-hospital care providers such as combat medics, non-medical first responders such as combat lifesavers, or self/buddy-aid. Within this context, the MBRP is interested in research proposals that address specific gaps in the area of military-relevant burns; therefore, the proposed research must address at least one of the following FY23 MBRP Focus Areas:

- **Atypical Burns:** Development and/or validation of methods to prevent, triage, and/or treat burns resulting from exposure to cold, radiation, directed energy weapons, or high voltage/combat-related electrical injuries. Novel interventions that go beyond topical agents or dressings are of particular interest.
- **Burn Injury During Mass Casualty Incidents:** Solutions to improve the triage, delivery, or capacity of care in the immediate aftermath of mass casualty incidents involving burn injuries (incendiary device explosions, multi-passenger vehicle fires, etc.).
- **Burn Injury-Related Complications:** Development and/or validation of methods to prevent, assess, and/or treat burn injury-related complications, including:
 - Over/under fluid resuscitation to include limited- or low-volume resuscitation
 - Acute Respiratory Distress Syndrome (ARDS)
 - Sepsis
 - Inhalation injuries

II.A.2. Award History

The MBRP Clinical Translational Research Award (CTRA) mechanism was first offered in FY19. Since then, 64 CTRA applications have been received, and 12 have been recommended for funding.

II.B. Award Information

The MBRP CTRA is intended to support the rapid implementation of clinical research (including clinical trials) with the potential to significantly impact burn care by applying promising and well-founded research findings to the care of the burn-injured patient, particularly at the point of injury, or during the early, acute phase of burn injury (Roles 1-3 of the military pathway of care).⁴

Impact: The overall impact of the proposed research is a key component of this award mechanism. The potential impact of the research, both short term and long term, in addressing one or more of the FY23 MBRP Focus Areas should be clearly described. Investigators are encouraged to consider the following characteristics as examples of how a project may demonstrate highly impactful research:

- Description of how the proposed research addresses a military need within Roles 1-3 of the military pathway of care⁴
- Explanation of how the project significantly advances the burn research field and the care of burn-injured service members in an austere or resource limited environment
- Description of how the proposed research will support the ability to provide care to burn injured patients at, or close to the point of injury, particularly by a combat medic (or equivalent), or a non-medical first responder

Relevance to Military Health: *The proposed research must be relevant to Service Members, Veterans, military beneficiaries, and/or the American public.* Investigators are encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:

- Explanation of how the project addresses an aspect of burn injuries typically associated with combat
- Description of how the results of the proposed research will address a military need

Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique data and research resources that the partners bring to the research effort, ultimately advancing burn research, which is of significance to the Service Member, military families, and the American public.

Inclusion of preliminary data relevant to the proposed clinical research is required.

⁴ https://www.jcs.mil/Portals/36/Documents/Doctrine/pubs/jp4_02ch1.pdf

The following are important aspects of the FY23 MBRP CTRA:

- The proposed clinical research study must be based on sound scientific rationale that is established through logical reasoning and critical review and analysis of the literature.
- Enrollment for the proposed clinical research study is expected to begin no later than **9** months after the award date.
- The application should demonstrate availability of, and access to, a suitable patient population that will support a meaningful outcome for the study.
- The application should include a clearly articulated statistical analysis plan, appropriate statistical expertise on the research team, and a power analysis reflecting sample size projections that will answer the objectives of the study.
- The application should include a Transition Plan (including potential funding and resources) showing how the product will progress to the next clinical phase and/or delivery to the market after the successful completion of the FY23 MBRP CTRA.
- Funded studies that contain clinical trials are required to register the study in the National Institutes of Health (NIH) clinical trials registry, www.clinicaltrials.gov, prior to initiation of the study. Refer to the General Application Instructions, Appendix 1, Section C, for further details.
- If proposing a clinical trial that involves the use of a drug that has not been approved by the Food and Drug Administration (FDA) for the proposed investigational use, an Investigational New Drug (IND) application to the FDA that meets all requirements under the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312) may be required and must be submitted to the FDA within 2 months (60 calendar days) of the award date. The IND should be specific for the product (i.e., the product should not represent a derivative or alternate version of the investigational agent described in the IND) and indication to be tested in the proposed clinical trial.
- If the investigational product is a device, evidence that an Investigational Device Exemption (IDE) application that meets all requirements under 21 CFR 812 has been submitted to the FDA within 2 months (60 calendar days) of the award date, or that the device is exempt or qualifies for an abbreviated IDE, is required. The IDE should be specific for the device (i.e., should not represent a derivative or modified version of the device described in the IDE application) and indication to be tested in the proposed clinical trial.
- If an IND or IDE has already been obtained for the investigational product, provide a copy of the acceptance from the FDA. The government reserves the right to withdraw funding if an IND or IDE is necessary but has not been submitted to the FDA within 2 months (60 calendar days) of the award date, or if documented status of the IND or IDE has not been obtained within 2 months (60 calendar days) of the award date.

Only clinical research and/or clinical trials will be considered for funding under this mechanism. Funding from this award mechanism must support clinical research involving human subjects; **animal research is not allowed under this funding opportunity.**

Clinical research encompasses research with patient samples, data, and interaction with patients that may or may not be considered a clinical trial. ***For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research.*** Clinical research is observational in nature and includes: (1) Research that does not seek to evaluate the effects of interventions. Research conducted with human subjects (or on material of human origin such as data, tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects, but does not seek to assess the effects of an intervention, qualifies as clinical research. Patient-oriented research may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to study the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human tissues that cannot be linked to a living individual. ***Note:*** Studies that meet the requirements for exemption under [§46.104\(d\)\(4\) of the Common Rule](#) are not considered clinical research as defined by CDMRP. Exemption category 4 refers to secondary research for which consent is not required.

A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

Funded trials are required to post a copy of the IRB-approved informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in 32 CFR 219.

The types of awards made under the program announcement will be assistance agreements. An assistance agreement is appropriate when the federal government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States instead of acquiring property or service for the direct benefit and use of the U.S. government. An assistance agreement can take the form of a grant or cooperative agreement. The level of involvement on the part of the DOD during project performance is the key factor in determining whether to award a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304). Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305), and the award will identify the specific substantial involvement. Substantial involvement may include, but is not limited to, collaboration, participation, or intervention in the research to be performed under the award. The award type, along with the start date, will be determined during the negotiation process.

The anticipated total costs budgeted for the entire period of performance for an FY23 MBRP CTRA should not exceed \$2M. Refer to [Section II.D.5, Funding Restrictions](#), for detailed funding information.

Awards will be made no later than September 30, 2024. For additional information refer to [Section II.F.1, Federal Award Notices](#).

The CDMRP expects to allot approximately \$4M to fund approximately two Clinical Translational Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY23 funding opportunity will be funded with FY23 funds, which will expire for use on September 30, 2029.

Research Involving Human Data, Human Anatomical Substances, Human Subjects, or Human Cadavers: All DOD-funded research involving new and ongoing research with human data, human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the USAMRDC Office of Human and Animal Research Oversight (OHARO), Office of Human Research Oversight (OHRO), prior to research implementation. This administrative review requirement is in addition to the local Institutional Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC approval at the time of application submission is *not* required; however, local IRB/EC approval is necessary prior to OHRO review. Allow up to 3 months to complete the OHRO regulatory review and approval process following submission of *all required and complete* documents to the OHRO. Refer to the General Application Instructions, Appendix 1, and the OHARO web page https://mrhc.health.mil/index.cfm/collaborate/research_protections/hrpo for additional information.

Multi-Institutional Clinical Studies: If the proposed research involves more than one institution, a written plan for single IRB review arrangements must be provided at the time of application submission or award negotiation. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements.

Use of DOD or Department of Veterans Affairs (VA) Resources: If the proposed research involves access to active-duty military and/or VA patient populations and/or DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to [Section II.D.2.b.ii, Full Application Submission Components](#), for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.

Encouraged DOD and/or VA Collaboration and Alignment: Military relevance is a key feature of this award. Therefore, Principal Investigators (PIs) are encouraged to collaborate, integrate, and/or align their projects with military and/or VA research laboratories and programs.

Although not a comprehensive list, [Appendix 2](#) lists websites that may be useful in identifying information about DOD and VA areas of research interest, ongoing research, or potential opportunities for collaboration.

The CDMRP intends that information, data, and research resources generated under awards funded by this program announcement be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 2, Section K.

II.C. Eligibility Information

II.C.1. Eligible Applicants

II.C.1.a. Organization: All organizations, including foreign organizations, foreign public entities, and international organizations, are eligible to apply.

Government Agencies Within the United States: Local, state, and federal government agencies are eligible to the extent that applications do not overlap with their fully funded internal programs. Such agencies are required to explain how their applications do not overlap with their internal programs.

As applications for this program announcement may be submitted by extramural and intramural organizations, these terms are defined below.

Extramural Organization: An eligible non-DOD organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, federal government organizations other than the DOD, and research institutes.

Intramural DOD Organization: A DOD laboratory, DOD military treatment facility, and/or DOD activity embedded within a civilian medical center. ***Intramural Submission: An application submitted by a DOD organization for an intramural investigator working within a DOD laboratory or military treatment facility or in a DOD activity embedded within a civilian medical center.***

The USAMRAA makes awards to eligible organizations, not to individuals.

II.C.1.b. Principal Investigator

Principal Investigators (PIs) at or above the level of Assistant Professor (or equivalent) may be named by the organization as the PI on the application.

An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.

The CDMRP strongly encourages all PIs to participate in a digital identifier initiative through Open Researcher and Contributor ID, Inc. (ORCID). Registration for a unique ORCID identifier can be done online at <https://orcid.org/>.

II.C.2. Cost Sharing

Cost sharing/matching is not an eligibility requirement.

II.C.3. Other

Organizations must be able to access **.gov** and **.mil** websites in order to fulfill the financial and technical deliverable requirements of the award and submit invoices for payment.

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 3.

Refer to [Section II.H.2, Administrative Actions](#), for a list of administrative actions that may be taken if a pre-application or application does not meet the administrative, eligibility, or ethical requirements defined in this program announcement.

II.D. Application and Submission Information

Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

Inclusion of classified research data within the application and/or proposing research of which the anticipated outcomes may be classified or deemed sensitive to national security concerns may result in application withdrawal. Refer to the General Application Instructions Appendix 2, Section E.

II.D.1. eBRAP and Grants.gov

The **electronic Biomedical Research Application Portal (eBRAP)** (<https://ebrap.org>) is a secure web-based system that allows PIs to submit their pre-applications, view and verify extramural full applications submitted to Grants.gov (<https://grants.gov>), receive communications from the CDMRP, and submit documentation during award negotiations and throughout the period of performance. eBRAP also allows intramural organizations to submit full applications following pre-application submission.

Grants.gov is a federal system required to be utilized by agencies to receive and process extramural grant applications. Full applications may only be submitted to Grants.gov after submission of a pre-application through eBRAP.

Contact information for the eBRAP Help Desk and the Grants.gov Contact Center can be found in [Section II.G, Federal Awarding Agency Contacts](#).

Extramural Submission:

- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at Grants.gov.

Intramural DOD Submission:

- Pre-application content and forms must be accessed and submitted at eBRAP.org.
- Full application packages must be accessed and submitted at eBRAP.org.

Note: Applications from an intramural DOD organization or from an extramural federal government organization may be submitted to Grants.gov through a research foundation.

II.D.2. Content and Form of the Application Submission

Submission is a two-step process requiring both ***pre-application*** (eBRAP.org) and ***full application*** (eBRAP.org or Grants.gov) as indicated below. The submission process should be started early to avoid missing deadlines. There are no grace periods. Full application submission guidelines differ for extramural (Grants.gov) and intramural (eBRAP.org) organizations (refer to [Table 1, Full Application Guidelines](#)).

The application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507 prior to the application submission deadline.

II.D.2.a. Step 1: Pre-Application Submission Content

During the pre-application process, eBRAP assigns each submission a unique log number. This unique eBRAP log number is required during the full application submission process.

To begin the pre-application process, first select whether the submitting organization is extramural or intramural, then confirm your selection or cancel. **Incorrect selection of extramural or intramural submission type will delay processing.**

If an error has been made in the selection of extramural versus intramural and the pre-application submission deadline has passed, the PI or Business Official must contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507 to request a change in designation.

All pre-application components must be submitted by the PI through eBRAP (<https://eBRAP.org>). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

The applicant organization and associated PI identified in the pre-application should be the same as those intended for the subsequent application submission. A change in PI or organization after submission of the pre-application may be allowed after review of a submitted written appeal (contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507) and at the discretion of the USAMRAA Grants Officer.

PIs with an ORCID identifier should enter that information in the appropriate field in the “My Profile” tab in the “Account Information” section of eBRAP.

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B, for additional information on pre-application submission):

- **Tab 1 – Application Information**

Submission of application information includes assignment of primary and secondary research classification codes, which may be found at <https://ebrap.org/eBRAP/public/Program.htm>. Applicants are strongly encouraged to review and confirm the codes prior to making their selection.

- **Tab 2 – Application Contacts**

Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this application” in Block 5 of the Grants.gov SF424 Research & Related Form). The Business Official must be either selected from the eBRAP list or invited in order for the pre-application to be submitted.

Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds to Block 5 on the Grants.gov SF424 Research & Related Form), and click on “Add Organizations to this Pre-application.” The organization(s) must be either selected from the eBRAP drop-down list or invited in order for the pre-application to be submitted.

It is recommended that PIs identify an Alternate Submitter in the event that assistance with pre-application submission is needed.

- **Tab 3 – Collaborators and Key Personnel**

Enter the names, organizations, and roles of all collaborators and key personnel associated with the application.

[FY23 MBRP Programmatic Panel members](#) should not be involved in any pre-application or application. For questions related to panel members and pre-applications or applications, refer to [Section II.H.2.c, Withdrawal](#), or contact the eBRAP Help Desk at help@eBRAP.org or 301-682-5507.

- **Tab 4 – Conflicts of Interest**

List all individuals other than collaborators and key personnel who may have a conflict of interest in the review of the application (including those with whom the PI has a personal or professional relationship).

- **Tab 5 – Pre-Application Files**

Note: Upload documents as individual PDF files unless otherwise noted. eBRAP will not allow a file to be uploaded if the number of pages exceeds the limit specified below.

- **Preproposal Narrative (three-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of uniform resource locators (URLs) that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

The Preproposal Narrative should include the following:

- **Background/Research Idea:** Briefly describe the scientific evidence that supports the proposed research, and include relevant literature citations. State the scientific rationale on which the proposed clinical research is based. Clearly specify if the proposed research will be regulated by the FDA or international regulatory agency, if applicable, based on intervention type and level of risk. If applicable, state the intervention to be tested and indicate the phase of clinical trial and/or class of device.
- **Research Strategy:** Concisely state the project’s hypothesis and/or objectives, and specific aims. Briefly describe the scientific approach and study design. Identify the resources to be utilized, the data to be analyzed, and/or the patient population to be engaged during the study.
- **Alignment With One or More Focus Areas:** Explain how the proposed work meets the intent of the award mechanism and addresses one or more of the FY23 MBRP Focus Areas. State explicitly how the proposed work would provide burn care solutions and in which role(s) of care the proposed study intervention is intended (e.g., prolonged field care, pre-hospital, emergency department, full-service hospital).
- **Impact and Military Benefit:** Describe how the proposed research would significantly advance the burn research field and/or the care of burn-injured patients and how the proposed research addresses military-relevant burn injuries. Note any DOD or VA collaborations.
- **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application *must be uploaded as individual files* and are limited to the following:
 - **References Cited (one-page limit):** List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers, and publisher, as appropriate).
 - **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.

- **Key Personnel Biographical Sketches (six-page limit per individual):** *All biographical sketches should be uploaded as a single combined file.* Biographical sketches should be used to demonstrate background and expertise through education, positions, publications, and previous work accomplished.

- **Tab 6 – Submit Pre-Application**

This tab must be completed for the pre-application to be accepted and processed.

Pre-Application Screening

- **Pre-Application Screening Criteria**

To determine the technical merits of the pre-application and the relevance to the mission of the Defense Health Program (DHP) and the MBRP, pre-applications will be screened based on the following criteria:

- **Background/Research Idea:** How well the scientific rationale supports the research idea.
- **Research Strategy:** How well the specific aims, patient population, and study design support the research idea and will achieve the desired outcomes. Whether resources and/or the identified patient population(s) are appropriate for the proposed research.
- **Alignment With One or More Focus Areas:** How well the proposed research addresses one or more of the FY23 MBRP Focus Areas and meets the intent of the award mechanism.
- **Impact and Military Benefit:** To what degree the proposed research, if successful, advances the burn research field and/or the care of burn-injured patients and how the proposed research addresses military-relevant burn injuries.

- **Notification of Pre-Application Screening Results**

Following the pre-application screening, PIs will be notified as to whether they are invited to submit applications; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-application. The estimated timeframe for notification of invitation to submit an application is indicated in [Section I, Overview of the Funding Opportunity](#). Invitations to submit a full application are based on the Pre-Application Screening Criteria listed above.

II.D.2.b. Step 2: Full Application Submission Content

Applications will not be accepted unless notification of invitation has been received.

The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.

Each application submission must include the completed full application package for this program announcement. The full application package is submitted by the Authorized Organizational Representative through Grants.gov (<https://grants.gov/>) for extramural organizations or through eBRAP (<https://ebrap.org/>) for intramural organizations. See Table 1 below for more specific guidelines.

II.D.2.b.i. Full Application Guidelines

Extramural organizations must submit full applications through Grants.gov. Applicants must create a Grants.gov Workspace for submission, which allows the application components to be completed online and routed through the applicant organization for review prior to submission. Applicants may choose to download and save individual PDF forms rather than filling out webforms in Workspace. A compatible version of Adobe Reader **must** be used to view, complete, and submit an application package consisting of PDF forms. If more than one person is entering text into an application package, the **same version** of Adobe Reader software should be used by each person. Check the version number of the Adobe software on each user’s computer to make sure the versions match. Using different versions of Adobe Reader may cause submission and/or save errors – even if each version is individually compatible with Grants.gov. Refer to the General Application Instructions, Section III, and the “Apply For Grants” page of Grants.gov (<https://www.grants.gov/web/grants/applicants/apply-for-grants.html>) for further information about the Grants.gov Workspace submission process. Submissions of extramural applications through eBRAP may be withdrawn.

Do not password protect any files of the application package, including the Project Narrative.

Table 1. Full Application Submission Guidelines

Extramural Submissions	Intramural DOD Submissions
Application Package Location	
Download application package components for HT9425-23-MBRP-CTRA from Grants.gov (https://grants.gov/) and create a Grants.gov Workspace. Workspace allows online completion of the application components and routing of the application package through the applicant organization for review prior to submission.	Download application package components for HT9425-23-MBRP-CTRA from eBRAP (https://ebrap.org/).
Full Application Package Components	
SF424 Research & Related Application for Federal Assistance Form: Refer to the General Application Instructions, Section III.A.1, for detailed information.	<p>Tab 1 – Summary: Provide a summary of the application information.</p> <p>Tab 2 – Application Contacts: This tab will be pre-populated by eBRAP; add Authorized Organizational Representative.</p>

Extramural Submissions	Intramural DOD Submissions
<p>Descriptions of each required file can be found under Full Application Submission Components:</p> <ul style="list-style-type: none"> • Attachments • Research & Related Personal Data • Research & Related Senior/Key Person Profile (Expanded) • Research & Related Budget • Project/Performance Site Location(s) Form • Research & Related Subaward Budget Attachment(s) Form 	<p>Tab 3 – Full Application Files: Upload files under each Application Component in eBRAP. Descriptions of each required file can be found under Full Application Submission Components:</p> <ul style="list-style-type: none"> • Attachments • Key Personnel • Budget • Performance Sites <p>Tab 4 – Application and Budget Data: Review and edit proposed project start date, proposed end date, and budget data pre-populated from the Budget Form.</p>
Application Package Submission	
<p>Create a Grants.gov Workspace. Add participants (investigators and Business Officials) to Workspace, complete all required forms, and check for errors before submission.</p> <p>Submit a Grants.gov Workspace Package. An application may be submitted through Workspace by clicking the “Sign and Submit” button on the “Manage Workspace” page, under the “Forms” tab. Grants.gov recommends submission of the application package at least 24-48 hours prior to the close date to allow time to correct any potential technical issues that may disrupt the application submission.</p> <p><i>Note:</i> If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID <i>prior to</i> the application submission deadline. <i>Do not password protect any files of the application package, including the Project Narrative.</i></p>	<p>Submit package components to eBRAP (https://ebrap.org).</p> <p>Tab 5 – Submit/Request Approval Full Application: After all components are uploaded and prior to the full application submission deadline, enter your password in the space provided next to “Enter Your Password Here” and press the “Submit Full Application” button. eBRAP will notify your Resource Manager/ Comptroller/Task Area Manager or equivalent Business Official by email. <i>Do not password protect any files of the application package, including the Project Narrative.</i></p>
<u>Application Verification Period</u>	
<p>The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package</p>	<p>After eBRAP has processed the full application, the organizational Resource Manager/ Comptroller/Task Area Manager or equivalent Business Official and PI will receive email notification of this status and will be able to view</p>

Extramural Submissions	Intramural DOD Submissions
<p>may be modified <i>with the exception of the Project Narrative and Research & Related Budget Form</i>.</p>	<p>and modify application components in eBRAP. During the application verification period, the full application package may be modified <i>with the exception of the Project Narrative and Research & Related Budget Form</i>. Your Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve prior to the application verification deadline.</p>
Further Information	
<p>Tracking a Grants.gov Workspace Package. After successfully submitting a Workspace package, a Grants.gov Tracking Number is automatically assigned to the package. The number will be listed on the “Confirmation” page that is generated after submission.</p> <p>Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.</p>	<p>Refer to the General Application Instructions, Section IV, for further information regarding eBRAP requirements.</p>

The full application package must be submitted using the unique eBRAP log number to avoid delays in application processing.

II.D.2.b.ii. Full Application Submission Components

- **Extramural Applications Only**

SF424 Research & Related Application for Federal Assistance Form: Refer to the General Application Instructions, Section III.A.1, for detailed information.

- **Extramural and Intramural Applications**

Attachments:

Each attachment to the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 4.

For all attachments, ensure that the file names are consistent with the guidance. Attachments will be rejected if the file names are longer than 50 characters or have incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, there are file size limits that may apply in some circumstances. Individual attachments may not exceed 20 megabytes (MB), and the file size for the entire full application package may not exceed 200 MB.

- **Attachment 1: Project Narrative (18-page limit): Upload as “ProjectNarrative.pdf”.** The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs (uniform resource locators) that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.
 - **Background:** Describe in detail the scientific rationale for the study and the clinical need(s) to be addressed. Identify one or more FY23 MBRP Focus Areas to be addressed. This section should establish the relevance of the study and explain the applicability of the proposed findings. Provide a literature review and describe the preliminary studies and/or preclinical data that led to the development of the proposed clinical research. Provide a summary of other relevant ongoing, planned, or completed clinical research or trials, and describe how the proposed study differs or builds on existing knowledge. Include a discussion of any current clinical use of the intervention under investigation, and/or details of its study in clinical trials for other indications (as applicable). The background section should clearly support the choice of study variables and should explain the basis for the study questions and/or study hypotheses. If the proposed clinical research is part of a larger ongoing effort, specifically identify the portions of the study that would be supported with funds from this award. The proposed clinical research study is expected to begin no later than 9 months after the award date.
 - **Objectives/Specific Aims/Hypotheses:** Provide a description of the purpose and objectives of the study with detailed specific aims and/or study questions/hypotheses. This information should agree with the primary aims and associated tasks described in the Statement of Work (SOW) ([Attachment 5](#)).
 - **Study Design:** Describe the type of study to be performed (e.g., treatment, prevention, diagnostic, retrospective, observational, comparative), the study phase or class (if applicable), and the study model (if applicable; e.g., single group, parallel, crossover). Outline the proposed methodology in sufficient detail to show a clear course of action.
 - Identify and briefly describe the product/intervention to be studied or tested (if applicable).
 - Define the primary and any secondary or interim endpoints/outcome measures, outline why they were chosen, and describe how and when they will be measured. Include a description of appropriate controls. Outline the timing and procedures planned during the follow-up period, if applicable.
 - If applicable, describe the study population, inclusion/exclusion criteria, and recruitment plan, and discuss how accrual goals will be achieved and how standards of care may impact the study population. Define each arm/study group

of the proposed research/trial and describe access and availability of human subjects for the clinical study, and the prospect of their participation and retention.

- Describe the plan for obtaining informed consent from human subjects.
 - Clearly identify all study risks, including potential safety concerns and adverse events. Describe the safety monitoring and reporting plan.
 - For multi-institutional studies, designate a single IRB and include a plan for the single IRB review process (foreign public entities/international organizations excepted).
 - Outline whether subjects, clinicians, data analysts, and/or others will be blinded during the study. Describe any other measures to be taken to reduce bias.
 - If using psychometric measures, describe their reliability and validity.
 - Describe potential problem areas (including slow accrual) and discuss alternative methods/approaches that may be employed to overcome them. Estimate the potential for subject attrition and/or loss to follow-up, and how such loss will be handled/mitigated.
- **Statistical and Data Analysis Plan:** Describe the statistical model and data analysis plan with respect to the study objectives. Specify the approximate number of human subjects to be enrolled. If multiple study sites are involved, state the approximate number to be enrolled at each site. Include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study. If a subpopulation of a recruited sample population will be used for analysis, complete a statistical analysis to ensure appropriate power can be achieved within the subpopulation study. Ensure sufficient information is provided to allow thorough evaluation of all statistical calculations during review of the application. Describe the data management plans, including how data will be collected, managed, reported, and analyzed.
- **Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”.** Start each document on a new page. If documents are scanned to PDF, the lowest resolution (100 to 150 dpi) should be used. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

- **References Cited:** List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).
- **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols.
- **Facilities, Existing Equipment, and Other Resources:** Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present government award under which the facilities or equipment items are now accountable. There is no form for this information.
- **Quad Chart:** Provide a Quad Chart for the proposed project. The format for the quad chart is available on the eBRAP “Funding Opportunities & Forms” web page at <https://ebrap.org/eBRAP/public/Program.htm>.
- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
- **Letters of Organizational Support (one-page limit per letter is recommended):** Provide a letter (or letters, if applicable) signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the program announcement, such as those from members of Congress, do not impact application review or funding decisions.
- **Letters of Collaboration (if applicable) (one-page limit per letter is recommended):** Provide a signed letter from each collaborating individual or organization demonstrating that the PI has the support or resources necessary for the proposed work. If an investigator at an intramural organization is named as a collaborator on an application submitted through an extramural organization, the application must include a letter from the collaborator’s Commander or Commanding Officer at the intramural organization that authorizes the collaborator’s involvement.
- **Letters of Commitment (if applicable; one page limit per letter is recommended):** If the proposed study involves use of a commercially produced investigational drug, device, or biologic, provide a letter of commitment from the commercial entity indicating availability of the product for the duration of the study, support for the proposed phase of research, and support for the indication to be tested.

- **Intellectual Property:** Information can be found in the 2 CFR 200.315, “Intangible Property.”
 - **Intellectual and Material Property Plan (if applicable):** Provide a plan for resolving intellectual and material property issues among participating organizations.
- **Data and Research Resources Sharing Plan:** Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to the General Application Instructions, Appendix 2, Section K, for more information about the CDMRP expectations for making data and research resources publicly available.
- **Use of DOD Resources (if applicable):** Provide a letter of support signed by the lowest-ranking person with approval authority confirming access to active-duty military populations and/or DOD resources or databases.
- **Use of VA Resources (if applicable):** Provide a letter of support from the VA Facility Director(s) or individual designated by the VA Facility Director(s), such as the Associate Chief of Staff for Research and Development (ACOS/R&D) or Clinical Service Chief, confirming access to VA patients, resources, and/or VA research space. For VA PIs, if the VA non-profit corporation is not identified as the applicant institution for administering the funds, include a letter from the VA ACOS/R&D confirming this arrangement and identifying the institution that will administer the funds associated with the proposed research.
- **Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”.** The technical abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. ***Do not include proprietary or confidential information.*** Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

The clarity and completeness within the space limits of the technical abstract are highly important for review of the application.

Technical abstracts should be written using the outline below.

- **Background:** Present the ideas and rationale behind the proposed clinical research, including how it addresses one or more FY23 MBRP Focus Areas.
- **Objective/Hypothesis:** State the objective to be reached and/or hypothesis to be tested.
- **Specific Aims:** State the specific aims of the study.
- **Study Design:** Briefly describe the study design, including appropriate controls.

- **Impact and Military Benefit:** State briefly how the proposed project, if successful, will have an impact on the burn research field and/or the care of burn-injured patients and how the research will ultimately improve the lives of burn patients. State the role(s) of care within which the proposed study intervention or product is intended (e.g., prolonged field care, pre-hospital, emergency department, full-service hospital). Note any DOD or VA collaborations.
- **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”.** The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. *Do not include proprietary or confidential information. Do not duplicate the technical abstract.* Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Lay abstracts should be written using the outline below.

- Describe the objectives and rationale for the proposed study in a manner *readily understood by readers without a background in science or medicine.*
- Describe the ultimate applicability and impact of the research.
 - How will one or more of the FY23 MBRP CTRA Focus Areas be addressed?
 - How will the findings of this research help burn-injured patients?
 - What are the potential clinical applications and benefits?
 - What is the projected timeline it may take to achieve the expected patient-related outcome?
 - Describe how the proposed project will benefit burn-injured Service Members, Veterans, and/or the general public.
 - Identify the role(s) of care within which the proposed study intervention is intended (e.g., prolonged field care, pre-hospital, emergency department, full-service hospital).
- **Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”.** The suggested SOW format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>). Recommended strategies for assembling the SOW can be found at <https://ebrap.org/eBRAP/public/Program.htm>.
 - For the Clinical Translational Research Award mechanism, refer to the “*Suggested SOW Strategy Clinical Research*” document for guidance on preparing the SOW. The SOW must be in PDF format prior to attaching.

- **Attachment 6: Intervention, if applicable (required for projects proposing clinical trials) (no page limit): Upload as “Intervention.pdf”. The Intervention attachment should include the components listed below.**
 - **Description of the Intervention:** Identify the intervention to be tested, and describe the particular outcomes, as it relates to one or more of the FY23 MBRP Focus Areas. Explain how the proposed intervention is feasible for use in its intended environment, and describe the rationale of the endpoints to be measured. As applicable, the description of the intervention should include the following components: complete name and composition, storage and handling information, source, dose, schedule, administration route, washout period, duration of the intervention, and concomitant medications allowed. Description of devices should include general concept of design, detailed operational instructions, any potential risks to users, and intended benefits. Other types of interventions should be fully described. Indicate who holds the intellectual property rights to the intervention, if applicable, and provide evidence to demonstrate that the PI has obtained access to those rights and/or intervention for conduct and duration of the clinical trial.

Summarize key preclinical pharmacological findings, dosage studies, and other clinical studies (if applicable) that examine the safety and stability (as appropriate) of the intervention.
 - **Study Procedures:** Describe the interaction with the human subject, including the study intervention that the subject will experience. Provide sufficient detail in chronological order for a person uninvolved in the study to understand what the human subject will experience. Provide a schedule (e.g., flowchart or diagram) of study evaluations and follow-up procedures. Clearly delineate research procedures from routine clinical procedures. Discuss how compliance with current Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) guidelines and other regulatory considerations will be established, monitored, and maintained, as applicable.
 - **Clinical Monitoring Plan:** Describe how the study will be conducted by and monitored for current ICH E6 (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) Good Clinical Practice (GCP) compliance, by an independent clinical trial monitor (or clinical research associate). The monitoring plan should describe the types of monitoring visits to be conducted, the intervals (based on level of risk), how corrective actions will be reported to the Sponsor and PI, and how they will be corrected and prevented by the clinical trial site/PI.
- **Attachment 7: Human Subject Recruitment and Safety Procedures (no page limit): Upload as “HumSubProc.pdf”. The Human Subject Recruitment and Safety Procedures attachment should include the components listed below.**
 - **Study Population:** Describe the target population (to whom the study findings will be generalized) and the nature, approximate number, pertinent demographic characteristics of the accessible population at the study site(s) (population from whom

the sample will be recruited/drawn), and the prospect of their participation. Provide a table of anticipated enrollment counts at each study site. Demonstrate that the research team has access to the proposed study population at each site, and describe the efforts that will be made to achieve accrual and retention goals. Furthermore, discuss past efforts in recruiting human subjects from the target population for previous clinical trials (if applicable). Address any potential barriers to accrual and contingency plans for addressing possible delays, including a mitigation plan for slow or low enrollment and/or attrition. Identify ongoing clinical trials that may compete for the same patient population and how they may impact enrollment progress. Describe how the proposed clinical trial might affect the daily lives of the individual human subjects participating in the study (e.g., medication use, overnight stays). Provide justification related to the scientific goals of the proposed study for limiting inclusion of any group by age, race, ethnicity, or sex/gender. ***For clinical trials proposing to include military personnel, refer to the General Application Instructions, Appendix 1, for more information.***

- **Inclusion/Exclusion Criteria:** List the inclusion and exclusion criteria for the proposed clinical trial. Inclusion/exclusion criteria should take into consideration the specific risk profile of the studies to be conducted and the standard of care for that patient population. Provide detailed justification for exclusions.

Inclusion of Women and Minorities in Study. Consistent with the Belmont Report, “Ethical Principles and Guidelines for the Protection of Human Subjects,” and congressional legislation, special attention is given to inclusion of women and/or minorities in studies funded or supported by the USAMRDC. This policy is intended to promote equity both in assuming the burdens and in receiving the benefits of human subjects research. Describe the strategy for the inclusion of women and minorities in the clinical trial appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex/gender, race, and ethnicity, and an accompanying rationale for the selection of subjects. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from IRB review) are exempt from this requirement. Provide an anticipated enrollment table(s) with the proposed enrollment distributed on the basis of sex/gender, race, and ethnicity. The Public Health Service (PHS) Inclusion Enrollment Report is a three-page fillable PDF form, which can be downloaded from eBRAP at <https://ebrap.org/eBRAP/public/Program.htm>

- **Description of the Recruitment Process:** Explain methods for identification of potential human subjects (e.g., medical record review, obtaining sampling lists, health care provider identification).
 - Describe the recruitment process in detail. Address who will identify potential human subjects, who will recruit them, and what methods will be used to recruit them.
 - If human subjects will be compensated for participation in the study, include a detailed description of and justification for the compensation plan.

- Describe the recruitment and advertisement materials. The recruitment materials should not be coercive or offer undue inducements and should accurately reflect the study.
- **Description of the Informed Consent Process:** Specifically describe the plan for obtaining informed consent from human subjects.
 - *For the proposed study, provide a draft, in English, of the Informed Consent Form.*
 - Identify who is responsible for explaining the study, answering questions, and obtaining informed consent. Include a plan for ensuring that human subjects' questions will be addressed during the consent process and throughout the trial.
 - Include information regarding the timing and location of the consent process.
 - Address issues relevant to the mental capacity of the potential human subject (e.g., altered capacity due to administration of any mind-altering substances such as tranquilizers, conscious sedation or anesthesia, brain injury, stress/life situations, or human subject age), if applicable.
 - Address how privacy and time for decision-making will be provided and whether or not the potential human subject will be allowed to discuss the study with anyone before making a decision.
 - Consider the need for obtaining ongoing consent or for re-assessing capacity over the course of a long-term study and describe any relevant procedures to assure continued consent.
 - Describe the plan for the consent of the individual's Legally Authorized Representative (LAR) to be obtained prior to the human subject's participation in the study. State law defines who may act as the LAR. The local IRB of record should be consulted for guidance regarding who can serve as LAR for research at the study site. *Note:* In compliance with 10 USC 980 (<https://www.gpo.gov/fdsys/pkg/USCODE-2011-title10/pdf/USCODE-2011-title10-subtitleA-partII-chap49-sec980.pdf>), the application must describe a clear intent to benefit for human subjects who cannot give their own consent to participate in the proposed clinical trial. If applicable, refer to the General Application Instructions, Appendix 1, for more information.
 - *Assent.* If minors or other populations that cannot provide informed consent are included in the proposed clinical trial, a plan to obtain assent (agreement) from those with capacity to provide it, or a justification for a waiver of assent, should be provided. PIs should consult with their local IRB to identify the conditions necessary for obtaining assent.
- **Screening Procedures:** List and describe any evaluations (e.g., laboratory procedures, history, or physical examination) that are required to determine

eligibility/suitability for study participation and the diagnostic criteria for entry.
Note: Some screening procedures may require a separate consent or a two-stage consent process.

– **Risks/Benefits Assessment:**

- **Foreseeable risks:** Clearly identify all study risks, including potential safety concerns and adverse events. Study risks include any risks that the human subject is exposed to as a result of participation in the clinical trial. Consider psychological, legal, social, and economic risks as well as physical risks. If the risks are unknown, this should be stated. If applicable, any potential risk to the study personnel should be identified.
- **Risk management and emergency response:**
 - ❖ Describe how safety surveillance and reporting to the IRB and FDA (if applicable) will be managed and conducted.
 - ❖ Describe all safety measures to minimize and/or eliminate risks to human subjects and study personnel or to manage unpreventable risks. Describe how the safety monitoring and reporting plan is appropriate for the level of risk. Include safeguards and planned responses such as dose reduction or stopping criteria based on toxicity grading scales or other predetermined alert values.
 - ❖ Discuss the overall plan for provision of emergency care or treatment for an adverse event for study-related injuries, including who will be responsible for the cost of such care.
 - ❖ Address any special precautions to be taken by the human subjects before, during, and after the study (e.g., medication washout periods, dietary restrictions, hydration, fasting, pregnancy prevention).
 - ❖ Describe any special care (e.g., wound dressing assistance, transportation due to side effects of study intervention impairing ability to drive) or equipment (e.g., thermometers, telemedicine equipment) needed for human subjects enrolled in the study.
 - ❖ If the IRB determines that a trial presents greater than minimal risk to human subjects, the DOD requires an independent research monitor with expertise consistent with the nature of risk(s) identified within the research protocol. If applicable, refer to the General Application Instructions, Appendix 1, Section B (Research Monitor Requirement), for more information on study reporting authorities and responsibilities of the research monitor.
- **Potential benefits:** Describe known and potential benefits of the study to the human subjects who will participate in the study. Articulate the importance of the knowledge to be gained as a result of the proposed research and if the population selected for participation in the trial stands to benefit from the gained knowledge.

Discuss why the potential risks to human subjects are reasonable in relation to the anticipated benefits to the human subjects and others that may be expected to result.

- **Attachment 8: Questionnaires and Other Data Collection Instruments, if applicable (no page limit): Upload as “DataCollection.pdf”.** The Questionnaires and Other Data Collection Instruments attachment should include a copy of the most recent version of questionnaires, data collection forms, rating scales, interview guides, or other instruments. For each instrument, describe how the information collected is related to the objectives of the study. Describe how and when the instrument(s) will be administered. Describe how the instrument(s) will be adapted to the subject population, if applicable.
- **Attachment 9: Data Management (no page limit): Upload as “Data_Manage.pdf”.** The Data Management attachment should include the components listed below.
 - **Data Management:** Describe all methods used for data collection, including the following:
 - **Identifiers:** Describe the unique identifiers or specific code system to be used to identify human subjects, if applicable.
 - **Confidentiality:**
 - ❖ Explain measures taken to protect the privacy of human subjects and maintain confidentiality of study data. Strategies to protect the privacy and confidentiality of study records, particularly those containing identifying information, should be addressed.
 - ❖ Address who will have access to study records, data, and specimens, including an acknowledgment that representatives of the DOD are eligible to review study records.
 - ❖ Address requirements for reporting sensitive information to state or local authorities.
 - **Data capture, verification, and disposition:** Describe how data will be captured and verified. Describe where data (both electronic and hard copy) will be stored, who will keep the data, how the data will be stored, the process for locking the database at study completion, and the length of time data will be stored. Describe the proposed database, how it will be developed and validated, and its capability to safeguard and maintain the integrity of the data. Describe the database lock process. For FDA-regulated studies, compliance with 21 CFR 11 and appropriate data standards (such as those established by the Clinical Data Interchange Standards Consortium) are required.
 - **Data reporting:** Describe how data will be reported and how it will be assured that the documentation will support a regulatory filing with the FDA or international regulatory agency, if applicable.

- **Sharing study results:** In cases where the human subject could possibly benefit medically or otherwise from the information, explain whether or not the results of screening and/or study participation will be shared with human subjects or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.
- **Laboratory Evaluations:**
 - **Specimens to be collected, schedule, and amount:** All specimens that will be collected for study purposes must be clearly stated. The collection schedule and amount of material collected must also be clearly described.
 - **Evaluations to be made:** Describe all evaluations that will be made for study purposes. Explain how the results of laboratory evaluations will be used to meet the objectives of the study (or to monitor safety of human subjects).
 - **Storage:** Describe specimen storage, including location of storage, how long specimens will be stored, any special conditions required, labeling, and specimen disposition. Outline the plan to store specimens for future use, including considerations for informed consent and providing human subjects with an opportunity to decline participation in the study.
 - **Labs performing evaluations and special precautions:** Identify the laboratory performing each evaluation, the applicable quality standard, and any special precautions that should be taken in handling the samples. Special precautions that should be taken by the human subject before, during, or after the laboratory procedure should be clearly defined. If transport of samples is required, describe provisions for ensuring proper storage during transport.
- **Attachment 10: Regulatory Strategy (no page limit): If submitting multiple documents, start each document on a new page. Combine and upload as a single file named “Regulatory.pdf”.** Answer the following questions and provide supporting documentation as applicable.
 - State the product/intervention name.

For products/interventions, or non-interventional studies, that do not require regulation by the FDA

- Explain why the product/intervention/proposed research is exempt from FDA oversight. Provide confirmation that the trial does not require regulation by the FDA in writing from the IRB of record or the FDA.
- No further information for Attachment 10 is required if the proposed study does not require regulation by the FDA

For products/interventions that require regulation by the FDA

- State whether the product is FDA-approved, -licensed, or -cleared, and marketed in the U.S.
- If the product is marketed in the U.S., state the product label indication. State whether the proposed research involves a change to the approved label indication for the route of administration, dosage level, and/or subject population. Indicate whether the proposed research involves a change that increases the risks associated with using the product. State whether the product is being promoted for an off-label use (where promotion involves the sale of a marketed product).
- If the product is not currently FDA-approved, -licensed, or -cleared, state the planned indication/use. Indicate whether the product would be classified as a drug, device, biologic, or combination product. Indicate whether the FDA has confirmed the proposed classification. Identify the regulatory sponsor. Include a signed sponsor commitment letter acknowledging the regulatory sponsor’s understanding of all sponsor responsibilities and commitment to oversee execution of the study.
- Identify the planned indication for the product label, if appropriate, and an outline of the development plan required to support that indication.
- If proposing a clinical trial that involves the use of a drug that has not been approved by the FDA for the proposed investigational use, an IND application to the FDA that meets all requirements under 21 CFR 312 may be required and must be submitted to the FDA ***within 2 months (60 calendar days) of the award date***. The IND should be specific for the product (i.e., the product should not represent a derivative or alternate version of the investigational agent described in the IND) and indication to be tested in the proposed clinical trial. For more information on IND applications, the FDA has provided guidance at <https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/investigationalnewdrugindication/default.htm>.
- If the investigational product is a device, evidence that an IDE application that meets all requirements under 21 CFR 812 has been submitted to the FDA or international regulatory agency, if applicable, ***within 2 months (60 calendar days) of the award date***, or that the device is exempt or qualifies for an abbreviated IDE, is required. The IDE should be specific for the device (i.e., should not represent a derivative or modified version of the device described in the IDE application) and indication to be tested in the proposed clinical trial.
- If an IND or IDE has already been obtained for the investigational product, provide a copy of the acceptance from the FDA or international regulatory agency, if applicable. The government reserves the right to withdraw funding if an IND or IDE is necessary but has not been submitted to the FDA or international regulatory agency, if applicable within 2 months (60 calendar days) of the award date, or if

documented status of the IND or IDE has not been obtained within 2 months (60 calendar days) of the award date.

- Provide the current status for manufacturing development (e.g., manufacturer’s name, GMP-compliant lots available, status of stability testing), non-clinical development (e.g., test facility name, status of pivotal GLP toxicology studies to support phase 1 testing), and clinical development (e.g., clinical site name, safety profile, status of any completed or ongoing clinical trials).
- Describe the overall regulatory strategy and product development plan that will support the planned product indication. Include a description of the numbers and types of studies proposed to reach approval, licensure, or clearance, the types of FDA or international regulatory agency, if applicable, meetings that will be held/planned, and the submission filing strategy. Include considerations for compliance with current GMP, GLP, and GCP guidelines. For investigator-sponsored regulatory applications (e.g., IND, IDE), include evidence of appropriate institutional support, including capabilities to ensure monitoring as required by the FDA or international regulatory agency.
- **Attachment 11: Study Personnel and Organization (no page limit): Start each document on a new page. Combine into one document and upload as “Personnel.pdf”.** The Study Personnel and Organization attachment should include the components listed below.
 - **Organizational Chart:** Provide an organizational chart that identifies key members of the study team and provides an outline of the governing structure for multi-institutional studies. Identify collaborating organizations, centers, and/or departments and name each person’s position on the project. Include any separate laboratory or testing center. Identify the data and clinical coordinating center(s) and note any involvement from Contract Research Organizations, if appropriate. Identify and provide justification for the inclusion of international sites, as appropriate. If applicable, identify the FDA or international regulatory agency, if applicable, regulatory sponsor and any external consultants or other experts who will assist with FDA applications. While there is no specified format for this information, a table(s) or diagram is recommended.
 - **Study Personnel Description:** Briefly describe the roles of the individuals listed in the organizational chart on the project. Describe relevant experience and qualifications that demonstrate appropriate expertise for the given role (e.g., statistical expertise, expertise in burn care, and clinical studies), including previous interactions with the FDA or international regulatory agency, if applicable. A study coordinator(s) should be included. Provide a plan for ensuring the standardization of procedures among staff and across sites (if applicable).
- **Attachment 12: Transition Plan (three-page limit): Upload as “Transition.pdf”.** Describe/discuss the methods and strategies proposed to move the product or intervention to the next phase of development (e.g., clinical trials, commercialization, and/or delivery

to the civilian or military market) after successful completion of the award. Applicants are encouraged to work with their organization's Technology Transfer Office (or equivalent) to develop the transition plan. **PIs are encouraged to explore developing relationships with industry and/or other funding agencies to facilitate moving the product into the next phase of development.** The post-award transition plan should include the components listed below.

- A description of collaborations and other resources that will be used to provide continuity of development.
- Details of the funding strategy to transition to the next level of development and/or commercialization (e.g., specific industry partners, specific internal and/or external funding opportunities to be applied for). Include a description of collaborations and other resources that will be used to provide continuity of development.
- For knowledge products, the description of collaborations and other resources that will provide continuity of development may include proposed development or modification of clinical practice guidelines and recommendations, provider training materials, patient brochures, and other clinical support tools, scientific journal publications, models, simulations, and applications. (A “knowledge product” is a non-materiel product that addresses an identified need, topic area, or capability gap; is based on current evidence and research; aims to transition into medical practice, training, tools, or to support materiel solutions [systems to develop, acquire, provide, and sustain medical solutions and capabilities]; and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.)
- A brief schedule and milestones for transitioning the product or intervention to the next phase of development (i.e., next-phase clinical trials, commercialization, delivery to the military or civilian market, incorporation into clinical practice, and/or approval by the FDA or international regulatory agency, if applicable).
- Ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award and the government's ability to access such products or technologies in the future.
- If applicable, a risk analysis for cost, schedule, manufacturability, and sustainability.
- **Attachment 13: Impact and Military Benefit Statement (three-page limit): Upload as “MilBen.pdf”.**
 - Identify the volunteer population(s) that will participate in the proposed study, and describe how they represent the target population that would benefit from the intervention as it relates to one or more of the FY23 MBRP Focus Areas.
 - Describe the short- and long-term impact of this study and how it will make an impact on the lives of individuals who sustain military-relevant burn injuries.

- Indicate whether the proposed burn care solution will require minimal, moderate, or substantial training for use.
 - Provide information about the incidence and/or prevalence of the project-relevant burn injury in military Service Members and Veterans, as well as the incidence in the general population, if appropriate and available.
 - Describe how the product or intervention represents an improvement over currently available interventions and/or standards of care.
 - Identify where along the military (and civilian) pathways of care the proposed product or intervention will be applied.
 - How well the results of the proposed research address a military need within the pre-hospital phase or Roles 1-3 of the military pathway of care.
 - Describe how the proposed study has the potential to improve the standard of care for management of military relevant burn injuries.
- **Attachment 14: Representations, if applicable (extramural submissions only): Upload as “RequiredReps.pdf”.** All extramural applicants must complete and submit the Required Representations template available on eBRAP (<https://ebrap.org/eBRAP/public/Program.htm>). For more information, see the General Application Instructions, Appendix 5, Section B, Representations.
 - **Attachment 15: Suggested Collaborating DOD Military Facility Budget Format, if applicable: Upload as “MFBudget.pdf”.** If a military facility (Military Health System facility, research laboratory, medical treatment facility, dental treatment facility, or a DOD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete a separate budget, using “Suggested Collaborating DOD Military Facility Budget Format”, available for download on the eBRAP “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>), including a budget justification, for each military facility as instructed. The costs per year should be included on the Grants.gov Research & Related Budget Form under subaward costs. Refer to the General Application Instructions, Section III.A.8, for detailed information.
- **Extramural and Intramural Applications**

To evaluate compliance with Title IX of the Education Amendments of 1972 (20 USC 1681[a] et seq.), the DOD is collecting certain demographic and career information to be able to assess the success rates of women who are proposed for key roles in applications in science, technology, engineering, and/or mathematics (STEM) disciplines. To enable this assessment, each application must include the following forms completed as indicated.

Research & Related Personal Data: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.3, and for intramural submissions (via

eBRAP), refer to the General Application Instructions, Section IV.A.2, for detailed information.

Research & Related Senior/Key Person Profile (Expanded): For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.4, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.3, for detailed information.

- PI Biographical Sketch (six-page limit): Upload as “Biosketch_LastName.pdf”. The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) in eBRAP. The NIH Biographical Sketch may also be used. All biographical sketches should be submitted in uneditable PDF format.
- PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.
 - For extramural submissions, refer to the General Application Instructions, Section III.A.4, for detailed information.
 - For intramural submissions, refer to the General Application Instructions, Section IV.A.3, for detailed information.
- Key Personnel Biographical Sketches (six-page limit each): Upload as “Biosketch_LastName.pdf”.
- Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf”.

Research & Related Budget: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.5, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.4, for detailed information.

Budget Justification (no page limit): Upload as “BudgetJustification.pdf”. The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

Project/Performance Site Location(s) Form: For extramural submissions (via Grants.gov), refer to the General Application Instructions, Section III.A.6, and for intramural submissions (via eBRAP), refer to the General Application Instructions, Section IV.A.5, for detailed information.

- **Extramural Applications Only**

Research & Related Subaward Budget Attachment(s) Form (if applicable): Refer to the General Application Instructions, Section III.A.7, for detailed information.

- **Extramural Subaward:** Complete the Research & Related Subaward Budget Form through Grants.gov. (Refer to the General Application Instructions, Section III.A.7, for detailed information.) Verify subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.
- **Intramural DOD Collaborator(s):** Complete the “Suggested Collaborating DOD Military Facility Budget Format” and upload to Grants.gov attachment form as [Attachment 15](#). (Refer to the General Application Instructions, Section IV.A.4, for detailed information.) Each Intramural DOD Collaborator should include costs per year on the Grants.gov Research & Related Budget Form under subaward costs.

II.D.3. Unique Entity Identifier (UEI) and System for Award Management (SAM)

The applicant organization must be registered as an entity in SAM (<https://www.sam.gov/SAM/>) and receive confirmation of an “Active” status before submitting an application through Grants.gov. ***As of April 2022, all federal awards including, but not limited to, contracts, grants, and cooperative agreements will use the UEI generated through SAM.gov.*** Refer to the General Application Instructions, Section III, for further information regarding Grants.gov requirements.

II.D.4. Submission Dates and Times

All submission dates and times are indicated in [Section I, Overview of the Funding Opportunity](#). Pre-application and application submissions are required. The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Failure to meet either of these deadlines will result in submission rejection.

Applicant Verification of Full Application Submission in eBRAP

For Both Extramural and Intramural Applicants: eBRAP allows an organization’s representatives and PIs to view and modify the full application submissions associated with them. Following retrieval and processing of the full application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify the full application submission. eBRAP will validate full application files against the specific program announcement requirements, and discrepancies will be noted in an email to the PI and in the “Full Application Files” tab in eBRAP. eBRAP does not confirm the accuracy of file content. Application viewing, modification, and verification in eBRAP are strongly recommended, but not required. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the program announcement. ***If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted prior to the application submission deadline. The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline.*** Other application components may be changed until the end of the application verification period. Verify that subaward budget(s) and budget justification forms are present in eBRAP during the application verification period. If these components are

missing, upload them to eBRAP before the end of the application verification period. After the end of the application verification period, the full application cannot be modified.

Extramural Submission: The full application package submitted to Grants.gov may be viewed and modified in eBRAP until the end of the application verification period. During the application verification period, the full application package, ***with the exception of the Project Narrative and Budget Form***, may be modified.

Intramural DOD Submission: After eBRAP has processed the full application, the organizational Resource Manager/Comptroller/Task Area Manager or equivalent Business Official and PI will receive email notification of the status and will be able to view and modify application components in eBRAP. During the application verification period, the full application package, ***with the exception of the Project Narrative and Budget Form***, may be modified. The Resource Manager/Comptroller/Task Area Manager or equivalent Business Official should log into eBRAP to review and to approve the application package prior to the application verification deadline.

For All Submissions: Verify that subaward budget(s) with budget justification are present in eBRAP during the application verification period. If these components are missing, upload them to eBRAP before the end of the application verification period.

II.D.5. Funding Restrictions

The maximum period of performance is **4** years.

The application's total costs budgeted for the entire period of performance should not exceed **\$2M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate.

All direct and indirect costs of any intramural or extramural subaward or contract must be included in the total direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **4** years.

For this award mechanism, direct costs must be requested for:

- Travel costs for the PI to present project information or disseminate project results at one DOD-sponsored meeting (the Military Health System Research Symposium and/or an MBRP-specific meeting) in Year 3 or 4 of the period of performance. These travel costs are in addition to those allowed for annual scientific/technical meetings.

May be requested for (not all-inclusive):

- Support for multi-institutional collaborations, including single IRB costs (if appropriate).

- Travel costs for one investigator to travel to one scientific/technical meeting per year, in addition to the required meeting described above, to disseminate project results from the FY22 MBRP CTRA.

Must not be requested for:

- Animal research costs
- Tuition

For extramural awards with an intragovernmental component, direct transfer of funds from an extramural award recipient to a DOD or other federal agency is not allowed except under very limited circumstances. Funding to intramural DOD and other federal agencies will be managed through a direct funds transfer. Intramural applicants are responsible for coordinating through their agency's procedures the use of contractual or assistance funding awards or other appropriate agreements to support extramural collaborators.

Refer to the General Application Instructions, Section III.A.5, for budget regulations and instructions for the Research & Related Budget. *For federal agencies or organizations collaborating with federal agencies, budget restrictions apply as are noted in the General Application Instructions, Section III.A.5.*

II.D.6. Other Submission Requirements

Refer to the General Application Instructions, Appendix 4, for detailed formatting guidelines.

II.E. Application Review Information

II.E.1. Criteria

II.E.1.a. Peer Review

To determine technical merit, all applications will be evaluated according to the following **scored criteria**, which are of equal importance:

- **Research Strategy and Feasibility**
 - How well the scientific rationale for the proposed research is supported by the preliminary data, critical review and analysis of the literature, and/or laboratory/preclinical evidence.
 - How well designed the study aims, hypotheses and/or objective(s), experimental design, methods, data collection procedures, and analyses are to answer clearly the clinical objective.
 - How well the application addresses the access and availability of human subjects for the clinical study and the prospect of their participation and retention.

- To what degree the recruitment plan will meet the needs of the proposed clinical study.
- Whether plans for initiating the clinical research within 9 months are described.
- How well potential problems (including slow accrual and attrition) are acknowledged and alternative approaches are addressed.
- To what degree the data collection instruments (e.g., questionnaires), if applicable, are appropriate to the proposed study.
- Whether the strategy for the inclusion of women and minorities and distribution of proposed enrollment are appropriate for the proposed research.
- **Impact and Military Benefit**
 - To what degree the proposed study population represents the target population that would benefit from the study as it relates to one or more of the FY23 MBRP Focus Areas.
 - How well the proposed study would impact the lives of individuals who sustain military-relevant burn injuries in both the short term and long term.
 - To what degree the proposed product or burn-care solution requires training for use (if applicable).
 - How well how the product or intervention represents an improvement over currently available interventions and/or standards of care.
 - To what degree the proposed research places emphasis on military-relevant burn injuries.
 - Whether incidence and/or prevalence of the problem supports the need for the proposed solution.
 - How well the results of the proposed research address a military need within Roles 1-3 of the military pathway of care.
 - To what degree the proposed research improves the standard of care for management of military relevant burn injuries.
- **Intervention** *(if applicable; required for applications proposing a clinical trial)*
 - Whether there is evidence of support, indicating access to the intervention, for the duration of the proposed clinical trial (if applicable).
 - Whether the proposed intervention is feasible for use in its intended environment, and endpoints are rational.
 - To what degree the intervention addresses the clinical need(s) described in the application.

- How the intervention compares with currently available interventions and/or standards of care.
- To what degree preclinical and/or clinical evidence is provided to support the safety of the intervention.
- How clearly delineated the research procedures are from routine clinical procedures.
- **Regulatory Strategy and Transition Plan**
 - Whether the regulatory strategy and transition plan are appropriate and well-described.
 - Whether the regulatory strategy and development plan to support the product indication or product label change, if applicable, are appropriate and well described.
 - Whether the application includes documentation that the study is exempt from FDA or international regulatory agency, if applicable, regulation, or, for products or interventions that require FDA or international regulatory agency, if applicable, regulation, that the plans for IND or IDE application submission to the FDA are appropriate.
 - Whether the identified next level of development and/or commercialization is realistic.
 - Whether the funding strategy described to bring the product/intervention to the next level of development (e.g., specific industry partners, internal and/or external funding opportunities to be applied for) is reasonable and achievable.
 - Whether plans to comply with current GMP, GLP, and GCP guidelines are appropriate.
 - Whether the proposed collaborations and other resources for providing continuity of development are established and/or achievable.
 - Whether the schedule and milestones for bringing the product/intervention to the next level of development (next-phase clinical trials, transition to industry, delivery to the market, incorporation into standard practice, and/or approval by the FDA or international regulatory agency, if applicable) are achievable.
 - How well the application identifies intellectual property ownership, demonstrates the appropriate access to all intellectual property rights necessary for development and commercialization, describes an appropriate intellectual and material property plan among participating organizations (if applicable), and addresses any impact of intellectual property issues on technology or product development and subsequent government access to technologies or products supported by this program announcement.
 - For investigator-sponsored regulatory applications (e.g., IND, IDE), whether there is evidence of appropriate institutional support, including capabilities to ensure monitoring as required by the FDA or international regulatory agency, if applicable.

- **Statistical and Data Analysis Plan**

- To what degree the statistical model and data analysis plan are suitable for the planned study.
- Whether the statistical plan, including sample size projections and power analysis, is adequate for the study.
- How well the data management plan describes how data will be collected, managed, reported, and analyzed.
- Whether the clinical study is designed with enough statistical power to lead to meaningful results.
- If applicable, whether the statistical plan compensates for the use of a subpopulation of a recruited sample population to ensure appropriate power can be achieved within the subpopulation study.

- **Ethical Considerations**

- How well the evidence shows that the procedures are consistent with sound research design.
- Whether the population selected to participate in the trial (if applicable) stands to benefit from the knowledge gained.
- Whether the level of risk to human subjects is minimized and how the safety monitoring and reporting plan is appropriate for the level of risk.
- To what degree the process for seeking informed consent is appropriate and whether safeguards are in place for vulnerable populations.

In addition, the following **unscored** criteria will also contribute to the overall evaluation of the application.

- **Personnel**

- To what degree the study team's background and expertise are appropriate to accomplish the proposed work (e.g., statistical expertise, expertise in burn care, and clinical studies).
- Whether the levels of effort of the study team members are appropriate for successful conduct of the proposed research.

- **Environment**

- To what degree the scientific environment, clinical setting, and accessibility of institutional resources support the clinical research at each participating center or institution (including collaborative arrangements).

- Whether there is evidence for appropriate institutional collaboration from each participating institution (if applicable).
- **Budget**
 - Whether the **total** costs exceed the allowable total maximum costs as published in the program announcement.
 - Whether the budget is appropriate for the proposed research.
- **Application Presentation**
 - To what extent the writing, clarity, and presentation of the application components influence the review.

II.E.1.b. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of the peer reviewers
- Relevance to the mission of the DHP and FY23 MBRP, as evidenced by the following:
 - Adherence to the intent of the award mechanism
 - Program portfolio composition
 - Relative impact and military benefit

II.E.2. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are made to the Commanding General, USAMRDC. *The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in [Section II.E.1.b, Programmatic Review](#).* Additional information about the two-tier process used by the CDMRP can be found at <https://cdmrp.health.mil/about/2tierRevProcess>. An information paper describing the funding recommendations and review process for the award mechanisms for the MBRP will be provided to the PI and posted on the CDMRP website.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement declaring that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review and approval process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization's application. Violations by panel members or applicants that compromise the confidentiality of the review and approval process may also result in suspension or debarment from federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with 18 USC 1905.

II.E.3. Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in 2 CFR 200.1, over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the Federal Awardee Performance and Integrity Information System (FAPIIS).

An applicant organization may review FAPIIS, accessible through SAM, and submit comments to FAPIIS on any information about the organization that a federal awarding agency previously entered and is currently available in FAPIIS.

The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics, and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

II.E.4. Anticipated Announcement and Federal Award Dates

All application review dates and times are indicated in [Section I, Overview of the Funding Opportunity](#).

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

II.F. Federal Award Administration Information

II.F.1. Federal Award Notices

Awards supported with FY23 funds are anticipated to be made no later than September 30, 2024. Refer to the General Application Instructions, Appendix 2, for additional award administration information.

After email notification of application review results through eBRAP, and if selected for funding, a representative from the USAMRAA will contact the Business Official authorized to negotiate on behalf of the PI's organization.

Pre-Award Costs: An institution of higher education, hospital, or other non-profit or for-profit organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award. Refer to the General Application Instructions, Section III.A.5.

Only an appointed USAMRAA Grants Officer may obligate the government to the expenditure of funds. No commitment on the part of the government should be inferred from discussions with any other individual. **The award document signed by the Grants Officer is the official authorizing document.**

Federal Government Organizations: Funding made to federal government organizations (to include intramural DOD organizations) will be executed through the Military Interdepartmental Purchase Request (MIPR) or Funding Authorization Document (FAD) process. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intramural applicants and collaborators are reminded to coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

II.F.1.a. PI Changes and Award Transfers

Changes in PI are not allowed, except under extenuating circumstances that will be evaluated on a case-by-case basis and at the discretion of the Grants Officer.

The organizational transfer of an award supporting a clinical trial is strongly discouraged and in most cases will not be allowed. Approval of a transfer request will be on a case-by-case basis at the discretion of the Grants Officer.

An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 2, Section B, for general information on organization or PI changes.

II.F.2. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

Refer to the General Application Instructions, Appendix 2, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 5, for general information regarding national policy requirements.

Refer to full text of the latest [DoD R&D General Terms and Conditions](#) and the [USAMRAA General Research Terms and Conditions: Addendum to the DoD R&D General Terms and Conditions](#) for further information.

Certification Regarding Disclosure of Funding Sources. The proposing entity must comply with Section 223(a) of the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021, which requires that the PI, Partnering PIs (if applicable), and all key personnel:

- Certify that the current and pending support provided on the application is current, accurate, and complete;
- Agree to update such disclosure at the request of the agency prior to the award of support and at any subsequent time the agency determines appropriate during the term of the award; and
- Have been made aware of the requirements under Section 223(a)(1) of this Act.

False, fictitious, or fraudulent statements or claims may result in criminal, civil, or administrative penalties (18 USC 1001).

II.F.3. Reporting

Refer to the General Application Instructions, Appendix 2, Section A, for general information on reporting requirements. ***If there are technical reporting requirement delinquencies for any existing USAMRAA-sponsored awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.***

Annual and quarterly progress reports as well as a final progress report will be required.

The Award Terms and Conditions will specify if additional and/or more frequent reporting is required.

Award Expiration Transition Plan: An Award Expiration Transition Plan must be submitted with the final progress report. Use the one-page template “Award Expiration Transition Plan,” available on the eBRAP “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) under the “Progress Report Formats” section. The Award Expiration Transition Plan must outline whether and how the research supported by this award will progress and must include source(s) of funding, either known or pending.

PHS Inclusion Enrollment Reporting Requirement: Enrollment reporting on the basis of sex/gender, race, and/or ethnicity will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on the “Funding Opportunities & Forms” web page (<https://ebrap.org/eBRAP/public/Program.htm>) in eBRAP.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant, and cooperative agreement awards with a cumulative total value greater than \$10M are required to provide information to FAPIIS about certain civil, criminal, and

administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil, and administrative proceedings as specified in the applicable Representations (see General Application Instructions, Appendix 5, Section B).

II.G. Federal Awarding Agency Contacts

II.G.1. eBRAP Help Desk

Questions related to program announcement content or submission requirements as well as questions related to the pre-application or intramural application submission through eBRAP should be directed to the eBRAP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET (closed on most U.S. federal holidays). Response times may vary depending upon the volume of inquiries.

Phone: 301-682-5507

Email: help@eBRAP.org

II.G.2. Grants.gov Contact Center

Questions related to extramural application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. federal holidays). Note that the eBRAP Help Desk is unable to provide technical assistance with Grants.gov submission.

Phone: 800-518-4726; International 1-606-545-5035

Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the “Synopsis” page for the program announcement or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

II.H. Other Information

II.H.1. Program Announcement and General Application Instructions Versions

Questions related to this program announcement should refer to the program name, the program announcement name, and the program announcement version code 803a. The program announcement numeric version code will match the General Application Instructions version code 803.

II.H.2. Administrative Actions

After receipt of pre-applications or applications, the following administrative actions may occur:

II.H.2.a. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative exceeds page limit.
- Preproposal Narrative is missing.

The following will result in administrative rejection of the application:

- Submission of an application for which a letter of invitation was not received.
- Pre-application was not submitted.
- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- Intervention ([Attachment 6](#)) is missing, *for applications proposing a clinical trial*.
- Regulatory Strategy ([Attachment 10](#)) is missing.
- The application does not propose either clinical research or a clinical trial.

II.H.2.b. Modification

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Preproposal Narrative and Project Narrative.
- Documents not requested will be removed.

II.H.2.c. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- An FY23 MBRP Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. *A list of the FY23 MBRP Programmatic Panel members can be found at <https://cdmrp.health.mil/mbrp/panels/panels23>.*
- The application fails to conform to this program announcement description.

- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in the preparation, research or other duties for submitted applications. For FY23, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (<https://cdmrp.health.mil/about/2tierRevProcess>). Applications that include names of personnel from either of these companies may be administratively withdrawn.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- Applications from extramural organizations, including non-DOD federal agencies, received through eBRAP may be withdrawn.
- Applications submitted by an intramural DOD organization may be withdrawn if the intramural organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to extramural collaborators.
- Application includes research data that are classified and/or proposes research of which the anticipated outcomes may be classified or deemed sensitive to national security will be considered for application withdrawal.
- The invited application proposes a different research project than that described in the pre-application.
- The PI does not meet the eligibility criteria.
- The proposed project includes animal research.
- The application submitted is essentially identical or proposes essentially the same research project to different funding opportunities within the same program and fiscal year.

II.H.2.d. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.

II.H.3. Application Submission Checklist

Application Components	Action	Completed
SF424 Research & Related Application for Federal Assistance (extramural submissions only)	Complete form as instructed	
Summary (Tab 1) and Application Contacts (Tab 2) (intramural submissions only)	Complete tabs as instructed	
Attachments	Project Narrative: Upload as Attachment 1 with file name "ProjectNarrative.pdf"	
	Supporting Documentation: Upload as Attachment 2 with file name "Support.pdf"	
	Technical Abstract: Upload as Attachment 3 with file name "TechAbs.pdf"	
	Lay Abstract: Upload as Attachment 4 with file name "LayAbs.pdf"	
	Statement of Work: Upload as Attachment 5 with file name "SOW.pdf"	
	Intervention: Upload as Attachment 6 with file name "Intervention.pdf" if applicable	
	Human Subject Recruitment and Safety Procedures: Upload as Attachment 7 with file name "HumSubProc.pdf"	
	Questionnaires and Other Data Collection Instruments: Upload as Attachment 8 with file name "DataCollection.pdf" if applicable	
	Data Management: Upload as Attachment 9 with file name "Data_Manage.pdf"	
	Regulatory Strategy: Upload as Attachment 10 with file name "Regulatory.pdf"	
	Study Personnel and Organization: Upload as Attachment 11 with file name "Personnel.pdf"	
	Transition Plan: Upload as Attachment 12 with file name "Transition.pdf"	
	Impact and Military Benefit Statement: Upload as Attachment 13 with file name "MilBen.pdf"	
	Representations (extramural submissions only): Upload as Attachment 14 with file name "RequiredReps.pdf"	

Application Components	Action	Completed
	Suggested Collaborating DOD Military Facility Budget Format: Upload as Attachment 15 with file name “MFBudget.pdf” if applicable	
Research & Related Personal Data	Complete form as instructed	
Research & Related Senior/Key Person Profile (Expanded)	Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field	
	Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field	
	Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field	
	Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field	
Research & Related Budget (extramural submissions only)	Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field	
Budget (intramural submissions only)	Suggested DOD Military Budget Format, including justification	
Project/Performance Site Location(s) Form	Complete form as instructed	
Research & Related Subaward Budget Attachment(s) Form, if applicable	Complete form as instructed	

APPENDIX 1: ACRONYM LIST

ACOS/R&D	Associate Chief of Staff for Research and Development
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
CTRA	Clinical Translational Research Award
DOD	Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FAPIIS	Federal Awardee Performance and Integrity Information System
FDA	Food and Drug Administration
FY	Fiscal Year
GCP	Good Clinical Practice
GLP	Good Laboratory Practice
GMP	Good Manufacturing Practice
IDE	Investigational Device Exemption
IND	Investigational New Drug
IRB	Institutional Review Board
LAR	Legally Authorized Representative
M	Million
MB	Megabytes
MBRP	Military Burn Research Program
MIPR	Military Interdepartmental Purchase Request
NIH	National Institutes of Health
OHARO	Office of Human and Animal Research Oversight
OHRO	Office of Human Research Oversight
ORCID	Open Researcher and Contributor ID, Inc.
PDF	Portable Document Format
PI	Principal Investigator
SAM	System for Award Management

SOW	Statement of Work
STEM	Science, Technology, Engineering, and/or Mathematics
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USAMRAA	U.S. Army Medical Research Acquisition Activity
USAMRDC	U.S. Army Medical Research and Development Command
USC	United States Code
VA	Department of Veterans Affairs

APPENDIX 2: DOD AND VA WEBSITES

Applicants are encouraged to integrate and/or align their research projects with DOD and/or VA research laboratories and programs. Collaboration with DOD and/or VA investigators is also encouraged. Below is a list of websites that may be useful in identifying additional information about DOD and VA areas of research interest, ongoing research, or potential opportunities for collaboration.

Air Force Office of Scientific Research

<https://www.afrl.af.mil/AFOSR/>

Air Force Research Laboratory

<https://www.afrl.af.mil/>

Armed Forces Radiobiology Research Institute

<https://afri.usuhs.edu/home>

Combat Casualty Care Research Program

<https://cccrp.health.mil/Pages/default.aspx>

Congressionally Directed Medical Research Programs

<https://cdmrp.health.mil/>

Defense Advanced Research Projects Agency

<https://www.darpa.mil/>

Defense Health Agency

<https://health.mil/About-MHS/OASDHA/Defense-Health-Agency/>

Defense Suicide Prevention Office

<https://www.dspo.mil/>

Defense Technical Information Center

<https://www.dtic.mil/>

Defense Threat Reduction Agency

<https://www.dtra.mil/>

Military Health System Research Symposium

<https://mhsrs.amedd.army.mil/SitePages/Home.aspx>

Military Infectious Diseases Research Program

<https://midrp.health.mil/>

Military Operational Medicine Research Program

<https://momrp.health.mil/>

Navy Bureau of Medicine and Surgery

<https://www.med.navy.mil/>

Naval Health Research Center

<https://www.med.navy.mil/Naval-Medical-Research-Command/R-D-Commands/Naval-Health-Research-Center/med.navy.afpims.mil/Nurse-Corps/>

Navy and Marine Corps Public Health Center

<https://www.med.navy.mil/Navy-Marine-Corps-Public-Health-Center/>

Naval Medical Research Command

<https://www.med.navy.mil/Naval-Medical-Research-Command/>

Office of Naval Research

<https://www.med.navy.mil/>

Office of the Under Secretary of Defense for Acquisition, Technology and Logistics

<https://www.acq.osd.mil/>

Telemedicine and Advanced Technology Research Center

<https://www.tatrc.org/>

Uniformed Services University of the Health Sciences

<https://www.usuhs.edu/research>

U.S. Air Force 59th Medical Wing

<https://www.59mdw.af.mil/>

U.S. Army Aeromedical Research
Laboratory
<https://usaarl.health.mil/>

U.S. Army Combat Capabilities
Development Command
<https://www.army.mil/devcom>

U.S. Army Institute of Surgical Research
<https://usaistr.health.mil/>

U.S. Army Medical Materiel Development
Activity
<https://usammda.health.mil/>

U.S. Army Medical Research and
Development Command
<https://mrdc.health.mil/>

U.S. Army Medical Research Institute of
Infectious Diseases
<https://usamriid.health.mil/>

U.S. Army Research Institute of
Environmental Medicine
<https://usariem.health.mil/>

U.S. Army Research Laboratory
<https://www.arl.army.mil/>

U.S. Army Sharp, Ready and Resilient
Directorate
<https://www.armyresilience.army.mil/sharp/index.html>

U.S. Department of Defense Blast Injury
Research Program
<https://blastinjuryresearch.health.mil/>

U.S. Department of Veterans Affairs, Office
of Research and Development
<https://www.research.va.gov/>

U.S. Naval Research Laboratory
<https://www.nrl.navy.mil/>

Walter Reed Army Institute of Research
<https://wrair.health.mil/>